242 related articles for article (PubMed ID: 37084092)
21. Role of Oligodendrocyte Dysfunction in Demyelination, Remyelination and Neurodegeneration in Multiple Sclerosis.
Dulamea AO
Adv Exp Med Biol; 2017; 958():91-127. PubMed ID: 28093710
[TBL] [Abstract][Full Text] [Related]
22. GD1a Overcomes Inhibition of Myelination by Fibronectin via Activation of Protein Kinase A: Implications for Multiple Sclerosis.
Qin J; Sikkema AH; van der Bij K; de Jonge JC; Klappe K; Nies V; Jonker JW; Kok JW; Hoekstra D; Baron W
J Neurosci; 2017 Oct; 37(41):9925-9938. PubMed ID: 28899916
[TBL] [Abstract][Full Text] [Related]
23. Multiple Sclerosis: Basic and Clinical.
Buzzard K; Chan WH; Kilpatrick T; Murray S
Adv Neurobiol; 2017; 15():211-252. PubMed ID: 28674983
[TBL] [Abstract][Full Text] [Related]
24. Knockdown of Lingo1b protein promotes myelination and oligodendrocyte differentiation in zebrafish.
Yin W; Hu B
Exp Neurol; 2014 Jan; 251():72-83. PubMed ID: 24262204
[TBL] [Abstract][Full Text] [Related]
25. A new model of cuprizone-mediated demyelination/remyelination.
Sachs HH; Bercury KK; Popescu DC; Narayanan SP; Macklin WB
ASN Neuro; 2014; 6(5):. PubMed ID: 25290063
[TBL] [Abstract][Full Text] [Related]
26. Remyelination in multiple sclerosis: what do we know and where are we going?
Williams A
Neurodegener Dis Manag; 2015; 5(1):49-59. PubMed ID: 25711454
[TBL] [Abstract][Full Text] [Related]
27. Nuclear hormone receptors in demyelinating diseases.
Zorrilla Veloz RI; McKenzie T; Palacios BE; Hu J
J Neuroendocrinol; 2022 Jul; 34(7):e13171. PubMed ID: 35734821
[TBL] [Abstract][Full Text] [Related]
28. Thyroid Hormone Potentially Benefits Multiple Sclerosis via Facilitating Remyelination.
Zhang M; Ma Z; Qin H; Yao Z
Mol Neurobiol; 2016 Sep; 53(7):4406-16. PubMed ID: 26243185
[TBL] [Abstract][Full Text] [Related]
29. The role of oligodendrocytes and oligodendrocyte progenitors in CNS remyelination.
Keirstead HS; Blakemore WF
Adv Exp Med Biol; 1999; 468():183-97. PubMed ID: 10635029
[TBL] [Abstract][Full Text] [Related]
30. Overcoming remyelination failure in multiple sclerosis and other myelin disorders.
Fancy SP; Kotter MR; Harrington EP; Huang JK; Zhao C; Rowitch DH; Franklin RJ
Exp Neurol; 2010 Sep; 225(1):18-23. PubMed ID: 20044992
[TBL] [Abstract][Full Text] [Related]
31. Can We Design a Nogo Receptor-Dependent Cellular Therapy to Target MS?
Kim MJ; Kang JH; Theotokis P; Grigoriadis N; Petratos S
Cells; 2018 Dec; 8(1):. PubMed ID: 30577457
[TBL] [Abstract][Full Text] [Related]
32. Inhibitory milieu at the multiple sclerosis lesion site and the challenges for remyelination.
Galloway DA; Gowing E; Setayeshgar S; Kothary R
Glia; 2020 May; 68(5):859-877. PubMed ID: 31441132
[TBL] [Abstract][Full Text] [Related]
33. The Molecular Basis for Remyelination Failure in Multiple Sclerosis.
Gruchot J; Weyers V; Göttle P; Förster M; Hartung HP; Küry P; Kremer D
Cells; 2019 Aug; 8(8):. PubMed ID: 31382620
[TBL] [Abstract][Full Text] [Related]
34. Targeting oligodendrocyte protection and remyelination in multiple sclerosis.
Zhang J; Kramer EG; Mahase S; Dutta DJ; Bonnamain V; Argaw AT; John GR
Mt Sinai J Med; 2011; 78(2):244-57. PubMed ID: 21425268
[TBL] [Abstract][Full Text] [Related]
35. Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis.
Pan S; Chan JR
Ann Neurol; 2021 Oct; 90(4):558-567. PubMed ID: 34402546
[TBL] [Abstract][Full Text] [Related]
36. LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence.
Rudick RA; Mi S; Sandrock AW
Expert Opin Biol Ther; 2008 Oct; 8(10):1561-70. PubMed ID: 18774923
[TBL] [Abstract][Full Text] [Related]
37. Intracellular signaling pathway regulation of myelination and remyelination in the CNS.
Gaesser JM; Fyffe-Maricich SL
Exp Neurol; 2016 Sep; 283(Pt B):501-11. PubMed ID: 26957369
[TBL] [Abstract][Full Text] [Related]
38. Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials.
Sutiwisesak R; Burns TC; Rodriguez M; Warrington AE
Expert Opin Investig Drugs; 2021 Aug; 30(8):857-876. PubMed ID: 34126015
[No Abstract] [Full Text] [Related]
39. Wnt signaling in remyelination in multiple sclerosis: friend or foe?
Xie C; Li Z; Zhang GX; Guan Y
Mol Neurobiol; 2014 Jun; 49(3):1117-25. PubMed ID: 24243343
[TBL] [Abstract][Full Text] [Related]
40. Mediators of oligodendrocyte differentiation during remyelination.
Patel JR; Klein RS
FEBS Lett; 2011 Dec; 585(23):3730-7. PubMed ID: 21539842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
